GlassScriptPhysician profile
Lauren E Rexroat
NPI 1013334408
$2,932.75
in general payments reported to CMS, 2019-2025
32 companies · $891 in 2025
The $891 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.83 · 2023: $857 · 2024: $1,143 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $384.41 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $256.10 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $193.54 | 2023-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $189.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $182.63 | 2023-2025 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $164.48 | 2023-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $154.90 | 2023-2024 | Austedo Xr, Austedo, Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.36 | 2023-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.17 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $79.65 | 2022-2024 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $67.02 | 2025 | |
| Glaxosmithkline, LLC. | $59.80 | 2023-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $51.96 | 2022-2023 | Belsomra, Steglatro |
| Lundbeck LLC | $44.68 | 2025 | Vyepti, Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.93 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $37.06 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.39 | 2024-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $33.36 | 2024-2025 | Zenpep |
| Jazz Pharmaceuticals INC. | $24.07 | 2024 | |
| Organon LLC | $23.83 | 2024 | |
| Mayne Pharma Commercial LLC | $23.81 | 2025 | |
| Shield Therapeutics INC | $20.84 | 2025 | |
| Globus Medical, INC. | $19.01 | 2025 | Senza |
| Cranial Technologies, INC | $18.43 | 2023 | Doc Band |
| Ibsa Pharma INC. | $18.05 | 2025 | Flector, Licart, Tirosint |
| Idorsia Pharmaceuticals US INC | $17.40 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $15.50 | 2023 | |
| Verona Pharma, INC. | $14.09 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.72 | 2024 | Gvoke Hypopen |
| Halozyme INC | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Rexroat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.